A new nanotechnology-based technique for regulating blood sugar in diabetics may give patients the ability to release insulin painlessly using a small ultrasound device, allowing them to go days between injections
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:13Ultrasound, nanoparticles may help diabetics avoid the needle
Scientists at Bonn University Hospital and at the Max Planck Institute for neurological research in Cologne have developed a method with which the chances of success of a surgical procedure for temporal lobe epilepsy can be accurately predicted. The rate of accurate predictions is more than 90%. When many nerve cells simultaneously fire in the brain, an epileptic seizure results. The most frequent form is temporal lobe epilepsy. It originates in one of the two temporal lobes which contain, among other things, important structures for co-ordinating memory. Because many patients do not respond to medication over the long term, the seizure focus in the affected temporal lobe is often removed in a neurosurgical procedure. However, approximately one-third of patients who undergo surgery do not experience any subsequent improvement.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:20Accurate prognosis for epilepsy patients
A new report released by the Epidemiological Research Unit on Perinatal Health and Women
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:08France looks to build on maternal mortality reduction
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:15New test for patients with sore throats cuts antibiotic use by nearly a third
After a diving accident left Jason DiSanto paralysed from the neck down in 2009, he had to learn how to navigate life from a powered wheelchair, which he controls with a sip-and-puff system. Users sip or puff air into a straw mounted on their wheelchair to execute four basic commands that drive the chair. But results from a new clinical study offer hope that sip-and-puff users like DiSanto could gain a higher level of independence than offered by this common assistive technology.
In the study, individuals with paralysis were able to use a tongue-controlled technology to access computers and execute commands for their wheelchairs at speeds that were significantly faster than those recorded in sip-and-puff wheelchairs, but with equal accuracy. This study is the first to show that the wireless and wearable Tongue Drive System outperforms sip-and-puff in controlling wheelchairs. Sip-and-puff is the most popular assistive technology for controlling a wheelchair.
The Tongue Drive System is controlled by the position of the user
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:10Clinical trial shows tongue-controlled wheelchair outperforms popular wheelchair navigation system
New research from Japan brings hope of a new treatment for asthma patients resistant to corticosteroids. In a study researchers from the RIKEN Center for Integrative Medical Sciences and Keio University in Japan report that a type of lymphocytes called natural helper (NH) cells plays a critical role in corticosteroid resistance and demonstrate that the anti-psychotic drug Pimozide can be used to overcome resistance to steroids in severe asthma patients.
Asthma is a chronic disease characterised by a persistent inflammation of the airways. The condition can be controlled with a moderate dose of inhaled corticosteroids in most patients. However, 5-10% of patients with ‘severe asthma’ respond poorly to a maximal dose of steroids. These patients experience uncontrolled and frequent asthma symptoms that have a profound impact on their quality of life and health care costs. Unveiling the mechanism leading to steroid resistance in these patients is therefore crucial for the development of a new, effective therapy.
T lymphocytes and NH cells in the asthmatic lung produce proteins named interleukin (IL)-5 and IL-13 that are responsible for severe airway inflammation. In asthma patients, inhaled steroids function by suppressing both T lymphocytes and NH cells.
However, in severe asthma patients, another protein called interleukin-33 (IL-33) produced in the airways strongly activates NH cells to produce IL-5 and IL-13, leading to severe airway inflammation.
In the current study, the researchers led by Drs Shigeo Koyasu from RIKEN and Koichiro Asano from Keio University, employed an experimental mouse model for airway inflammation to study the pathway leading to IL-33-mediated NH activation. Their research shows that NH resistance to steroids is induced by the protein thymic stromal lymphopoietin (TSLP), present in the airways of severe asthma patients.
The team tested reagents that block the intracellular signals triggered by TSLP in NH cells. They identified one drug, Pimozide, an approved anti-psychotic drug, that restored the effects of steroids on NH cells.
‘Therefore, administration of Pimozide or related drugs would be an effective treatment in human severe asthmatic patients,’ conclude the authors.
RIKEN
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:18Hope of new treatment for severe asthma patients
Finnish company Merivaara is launching a new version of its integrated operating room system, OpenOR
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:06Merivaara teams up with Barco to introduce cutting-edge integrated operating room solution
Nurses caring for ostomy patients will now be equipped with an essential new tool that provides them with the first comprehensive guide to optimise ostomy management and enhance patient safety.
Janice Beitz, a professor at the Rutgers School of Nursing
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:13Nursing scholar helps develop new ostomy care resource
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.